These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23689207)

  • 1. Acceleration of drug development: a collaboration of many stakeholders.
    Reynolds KS
    Clin Pharmacol Ther; 2013 Jun; 93(6):455-9. PubMed ID: 23689207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation.
    Zineh I; Woodcock J
    Clin Pharmacol Ther; 2013 Jun; 93(6):515-25. PubMed ID: 23571772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL; Myers RT; Goodsaid F
    Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 5. Re-engineering drug discovery and development.
    FitzGerald GA
    LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The critical path initiative: leveraging collaborations to enhance regulatory science.
    Barratt RA; Bowens SL; McCune SK; Johannessen JN; Buckman SY
    Clin Pharmacol Ther; 2012 Mar; 91(3):380-3. PubMed ID: 22343813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competitors try collaboration to speed drug development.
    Patlak M
    J Natl Cancer Inst; 2010 Jun; 102(12):841-3. PubMed ID: 20530762
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug development: current challenges and federal initiatives.
    Strawbridge S; Hobbs L
    Conn Med; 2014; 78(10):595-600. PubMed ID: 25745738
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory watch: FDA guidance on co-developing investigational drugs.
    Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulatory Watch: Impact of breakthrough therapy designation on cancer drug development.
    Shea M; Ostermann L; Hohman R; Roberts S; Kozak M; Dull R; Allen J; Sigal E
    Nat Rev Drug Discov; 2016 Mar; 15(3):152. PubMed ID: 26931085
    [No Abstract]   [Full Text] [Related]  

  • 11. Improving the FDA's advisory committee process.
    Brass EP; Hiatt WR
    J Clin Pharmacol; 2012 Aug; 52(8):1277-83. PubMed ID: 21908879
    [No Abstract]   [Full Text] [Related]  

  • 12. Patient-Focused Drug Development: A New Direction for Collaboration.
    Perfetto EM; Burke L; Oehrlein EM; Epstein RS
    Med Care; 2015 Jan; 53(1):9-17. PubMed ID: 25494232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory watch: crossing the regulatory finish line.
    Tse MT
    Nat Rev Drug Discov; 2012 Jun; 11(7):509. PubMed ID: 22743970
    [No Abstract]   [Full Text] [Related]  

  • 14. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-based drug development: a rational approach to efficiently accelerate drug development.
    Milligan PA; Brown MJ; Marchant B; Martin SW; van der Graaf PH; Benson N; Nucci G; Nichols DJ; Boyd RA; Mandema JW; Krishnaswami S; Zwillich S; Gruben D; Anziano RJ; Stock TC; Lalonde RL
    Clin Pharmacol Ther; 2013 Jun; 93(6):502-14. PubMed ID: 23588322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-inventing clinical trials through TransCelerate.
    Gill D
    Nat Rev Drug Discov; 2014 Nov; 13(11):787-8. PubMed ID: 25359361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 18. Working together to enhance the efficiency of medical product development.
    Sanhai WR
    J Nucl Med; 2008 Jun; 49(6):43N-45N. PubMed ID: 18511823
    [No Abstract]   [Full Text] [Related]  

  • 19. Beyond biomarkers: an opportunity to address the 'pharmacodynamic gap' in pediatric drug development.
    Kearns GL
    Biomark Med; 2010 Dec; 4(6):783-6. PubMed ID: 21133695
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS
    N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.